• Gyre Therapeutics swung to a third-quarter 2026 net loss of $2.48 million from a year-earlier profit.
• Revenue rose to $32.93 million, while general and administrative expense climbed 39% to $8.92 million year over year.
• An NMPA decision on F351 is expected by end-2026 or first-quarter 2027, with launch anticipated in first-half 2027 if approved.
• Full-year 2026 revenue guidance remained unchanged at $100.5 million to $111 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051607PRIMZONEFULLFEED9871759) on November 05, 2026, and is solely responsible for the information contained therein.